Exclusive Summary

• Supported by EMA GMP certification and marketing authorizations in 27 EU nations, enabling immediate distribution without registration delays and facilitating rapid global market entry.
• Targets a massive post-operative pain market driven by over 300 million global surgeries per year, perfectly aligning with ERAS guidelines for opioid-sparing multimodal analgesia.
• Serves as the only available injectable selective COX-2 inhibitor, delivering exceptional clinical value by overcoming the bleeding and gastrointestinal risks inherent to traditional NSAIDs.
• With originator patents expired, leveraging China's cost-efficient, integrated supply chain provides European-standard quality at a disruptive price, ensuring superior margins for distribution partners.